Review

. 2020 Jul;50(7):798-804.

doi: 10.1111/imj.14889.

Practical management of inflammatory bowel disease patients during the COVID-19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty

Al-Ani Aysha¹, Clarissa Rentsch¹, Ralley Prentice¹, Doug Johnson², Robert V Bryant^{3

4}, Mark G Ward^{5

6}, Samuel P Costello^{3

4}, Peter Lewindon⁷, Simon Ghaly⁸, Susan J Connor^{9

10

11}, Jakob Begun^{12

13}, Britt Christensen^{1

5}

Affiliations

¹ Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
² Victorian Infectious Diseases Unit, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
³ Department of Gastroenterology, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
⁴ School of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, South Australia, Australia.
⁵ Department of Gastroenterology, Monash University, Melbourne, Victoria, Australia.
⁶ Department of Gastroenterology, The Alfred Hospital, Melbourne, Victoria, Australia.
⁷ Department of Gastroenterology, Queensland Children's Hospital, Brisbane, Queensland, Australia.
⁸ Department of Gastroenterology, St Vincent's Hospital, Sydney, New South Wales, Australia.
⁹ Department of Gastroenterology, Liverpool Hospital, Sydney, New South Wales, Australia.
¹⁰ South Western Sydney Clinical School, University of NSW, Sydney, New South Wales, Australia.
¹¹ Department of Gastroenterology, Ingham Institute for Applied Medical Research, Sydney, New South Wales, Australia.
¹² Department of Gastroenterology, Mater Hospital Brisbane, Brisbane, Queensland, Australia.
¹³ Mater Research Institute, The University of Queensland, Brisbane, Queensland, Australia.

PMID: 32656985
PMCID: PMC7405147
DOI: 10.1111/imj.14889

Review

Practical management of inflammatory bowel disease patients during the COVID-19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty

Al-Ani Aysha et al. Intern Med J. 2020 Jul.

. 2020 Jul;50(7):798-804.

doi: 10.1111/imj.14889.

Authors

Affiliations

¹ Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
² Victorian Infectious Diseases Unit, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
³ Department of Gastroenterology, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
⁴ School of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, South Australia, Australia.
⁵ Department of Gastroenterology, Monash University, Melbourne, Victoria, Australia.
⁶ Department of Gastroenterology, The Alfred Hospital, Melbourne, Victoria, Australia.
⁷ Department of Gastroenterology, Queensland Children's Hospital, Brisbane, Queensland, Australia.
⁸ Department of Gastroenterology, St Vincent's Hospital, Sydney, New South Wales, Australia.
⁹ Department of Gastroenterology, Liverpool Hospital, Sydney, New South Wales, Australia.
¹⁰ South Western Sydney Clinical School, University of NSW, Sydney, New South Wales, Australia.
¹¹ Department of Gastroenterology, Ingham Institute for Applied Medical Research, Sydney, New South Wales, Australia.
¹² Department of Gastroenterology, Mater Hospital Brisbane, Brisbane, Queensland, Australia.
¹³ Mater Research Institute, The University of Queensland, Brisbane, Queensland, Australia.

PMID: 32656985
PMCID: PMC7405147
DOI: 10.1111/imj.14889

Abstract

The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has emerged as a public health emergency and challenged healthcare systems globally. In a minority of patients, SARS-CoV-2 manifests with a severe acute respiratory illness and currently there is insufficient data regarding the virulence of COVID-19 in inflammatory bowel disease patients taking immunosuppressive therapy. This review aims to summarise the current literature and provide guidance on the management of inflammatory bowel disease patients in the context of the COVID-19 pandemic in the Australasian setting.

Keywords: COVID-19; Crohn disease; SARS-CoV-2; immunosuppression; inflammatory bowel disease; ulcerative colitis.

PubMed Disclaimer

Cited by

COVID-19: looking backward.
Woolley I, Steinfort D, Szer J. Woolley I, et al. Intern Med J. 2021 Aug;51(8):1203-1204. doi: 10.1111/imj.15461. Intern Med J. 2021. PMID: 34423545 Free PMC article. No abstract available.
Life changes, self-prevention, knowledge and mental health among inflammatory bowel disease patients during COVID-19 pandemic: a cross-sectional study.
He S, Xiao T, Xia Y. He S, et al. Front Public Health. 2024 Jun 12;12:1416880. doi: 10.3389/fpubh.2024.1416880. eCollection 2024. Front Public Health. 2024. PMID: 38932786 Free PMC article.
Gastrointestinal and renal complications in SARS-CoV-2-infected patients: Role of immune system.
Maghool F, Valiani A, Safari T, Emami MH, Mohammadzadeh S. Maghool F, et al. Scand J Immunol. 2021 Apr;93(4):e12999. doi: 10.1111/sji.12999. Epub 2020 Dec 7. Scand J Immunol. 2021. PMID: 33190306 Free PMC article. Review.
Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic.
Lin S, Lau LH, Chanchlani N, Kennedy NA, Ng SC. Lin S, et al. Gut. 2022 Jul;71(7):1426-1439. doi: 10.1136/gutjnl-2021-326784. Epub 2022 Apr 27. Gut. 2022. PMID: 35477864 Free PMC article. Review.
Transmembrane serine protease 2 and angiotensin-converting enzyme 2 anti-inflammatory receptors for COVID-19/inflammatory bowel diseases treatment.
Lashgari NA, Momeni Roudsari N, Momtaz S, Abdolghaffari AH. Lashgari NA, et al. World J Gastroenterol. 2021 Dec 14;27(46):7943-7955. doi: 10.3748/wjg.v27.i46.7943. World J Gastroenterol. 2021. PMID: 35046622 Free PMC article. Review.

See all "Cited by" articles

References

1. Kang L, Li Y, Hu S, Chen M, Yang C, Yang BX et al The mental health of medical workers in Wuhan, China dealing with the 2019 novel coronavirus. Lancet Psychiatry 2020; 7: e14. - PMC - PubMed
1. Al‐Ani A, Prentice R, Rentsch C, Johnson D, Ardalan Z, Heerasing N et al Review article: prevention, diagnosis and managment of COVID‐19 in the IBD patient. Aliment Pharmacol Ther 2020; 52: 54–72. - PMC - PubMed
1. Hoffmann M, Kleine‐Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S et al SARS‐CoV‐2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271–80.e8. - PMC - PubMed
1. Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID‐19 and the possibility of faecal transmission. Aliment Pharmacol Ther 2020; 51: 843–51. - PMC - PubMed
1. Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J et al Clinical characteristics of COVID‐19 patients with digestive symptoms in Hubei, China: a descriptive, cross‐sectional, multicenter study. Am J Gastroenterol 2020; 115: 766–73 - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Practical management of inflammatory bowel disease patients during the COVID-19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty

Affiliations

Practical management of inflammatory bowel disease patients during the COVID-19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Miscellaneous

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Miscellaneous